New drug shows promise in reducing aortic valve surgeries
More information: Bin Zhang et al, Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow ...
Healio10d
Q&A: Novel drug may replace ‘watchful waiting’ approach to aortic stenosis care
A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...
Hosted on MSN1mon
Ataciguat's Headway in Aortic Stenosis; Baby Pacemakers; AI-ECG Tool for the ED?
The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies.
CU Boulder News & Events8y
Ricardo Stephen
Stephen, R., Palczewski, K., Sousa, M.C. (2008) Ca2+-dependent regulation of phototransduction. Photochem. And Photobiol. 84. 903-910 Stephen, R. (2008) Structural ...
Taiwan News3mon
Inhaled Nitric Oxide Market Share 2025 Comprehensive Insights, Growth Factors Analysis, Size, Innovations and Business Outlook till 2033
Nitric oxide (iNO) is selective pulmonary vasodilation and is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture nitric oxide delivery system. Nitric oxide ...